Neuro-Oncology Reviews
Volume
26 Number 25
10 November 2024
Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 25, 10 November
Ghasemi E, Mondanizadeh M, Almasi-Hashiani A, Mahboobi E.
The
significance of miR-124 in the diagnosis and prognosis of glioma:
A systematic review.
PLoS
One. 2024 Nov 1;19(11):e0312250. doi:
10.1371/journal.pone.0312250. PMID:
39485747. Review. ˍ
Satish S, Athavale M, Kharkar PS.
Targeted
therapies for Glioblastoma multiforme (GBM): State-of-the-art and
future prospects.
Drug
Dev Res. 2024 Nov 1;85(7):e22261. doi:
10.1002/ddr.22261. PMID:
39485272. Review˰ ˍ
Beylerli O, Gareev I, Ilyasova T, Musaev E, Chekhonin V.
The
Mechanism of Action of Exosomes Derived from Glioblastoma Cells.
Curr
Med Chem. 2024 Nov 4. doi:
10.2174/0109298673344390241017065119. PMID:
39501957. Review˰ ˍ
Grabenweger R, Völz D, Weck C, Hau P, Paal P, Bumes E.
Spirituality in Professional
Patient-Centered Care for Adults with Primary Brain Tumors: An
Exploratory Scoping Review.
J
Relig Health. 2024 Nov 5. doi:
10.1007/s10943-024-02161-x. PMID:
39500854. Review. ˍ
Ritchey
AK
et
al., PDQ Pediatric Treatment Editorial Board.
Childhood
Ependymoma: Patient
Version.
PDQ
Cancer Inf Summ.
2024
Nov
5. NCBI Bookshelf ID:
NBK65742.
PMID:
26389185.
Review
Malone K, LaCasse E, Beug ST.
Cell
death in glioblastoma and the central
nervous system.
Cell
Oncol (Dordr). 2024 Nov 6. doi:
10.1007/s13402-024-01007-8. PMID:
39503973. Review. ˍ
Wen PY.
Progress in treatment of
gliomas.
Curr
Opin Neurol. 2024 Nov 7;37(6):655-656. doi:
10.1097/WCO.0000000000001324. PMID:
39498845. Editorial. ˍ
Ospina JP, Wen PY.
Medical and
neurologic management of brain tumor patients.
Curr
Opin Neurol. 2024 Sep 3;37(6):657-665. doi:
10.1097/WCO.0000000000001315. PMID:
39221926. Recommendations. ˍ
Epstein JE, Pople CB, Meng Y, Lipsman N.
An
update on the role of focused ultrasound in neuro-oncology.
Curr
Opin Neurol. 2024 Oct 4;37(6):682-692. doi:
10.1097/WCO.0000000000001314. PMID:
39498847. Review. ˍ
Song KW, Scott BJ.
CAR T-cell therapy
for gliomas.
Curr
Opin Neurol. 2024 Oct 9;37(6):672-681. doi:
10.1097/WCO.0000000000001318. PMID:
39498846. Review. ˍ
González-Johnson L, Fariña A, Farías G,
Zomosa G, Pinilla-González V, Rojas-Solé C.
Exploring Neuroprotection against
Radiation-Induced Brain Injury: A
Review of Key Compounds.
NeuroSci.
2024 Oct 12;5(4):462-484. doi:
10.3390/neurosci5040034. PMID:
39484304. Review. ˍ
Dai J, Song S, Chen P, Huang Q, Duan H.
Analyzing
research trends in glioblastoma metabolism: a bibliometric review.
Front
Immunol. 2024 Oct 18;15:1444305. doi:
10.3389/fimmu.2024.1444305. PMID:
39493751. Bibiometric analysis. ˍ
Broggi G, Mazzucchelli M, Salzano S, Barbagallo GMV, Certo F,
Zanelli M, Palicelli A, Zizzo M, Koufopoulos N, Magro G,
Caltabiano R.
The emerging role of
artificial intelligence in neuropathology: Where are we and where
do we want to go?
Pathol
Res Pract. 2024 Oct 23;263:155671. doi:
10.1016/j.prp.2024.155671. PMID:
39490225. Review. ˍ
Zhang L, Wang Y, Cai X, Mao X, Sun H.
Deciphering
the CNS-glioma dialogue: Advanced insights into CNS-glioma
communication pathways and their therapeutic potential.
J
Cent Nerv Syst Dis. 2024 Oct 23;16:11795735241292188.
doi:
10.1177/11795735241292188. PMID:
39493257. Review. ˍ
Mohamed AH, Obeid RA, Fadhil AA, Amir AA, Adhab ZH, Jabouri EA,
Ahmad I, Alshahrani MY.
BTLA and HVEM:
Emerging players in the tumor microenvironment and cancer
progression.
Cytokine.
2023 Oct 28;172:156412. doi:
10.1016/j.cyto.2023.156412. PMID:
39492110. Review˰ ˍ
Villanueva-Meyer JE, Bakas S, Tiwari P, Lupo JM, Calabrese E,
Davatzikos C, Bi WL, Ismail M, Akbari H, Lohmann P, Booth TC,
Wiestler B, Aerts HJWL, Rasool G, Tonn JC, Nowosielski M, Jain R,
Colen RR, Pati S, Baid U, Vollmuth P, Macdonald D, Vogelbaum MA,
Chang SM, Huang RY, Galldiks N; Response Assessment in Neuro
Oncology (RANO) group.
Artificial
Intelligence for Response Assessment in Neuro Oncology (AI-RANO),
part 1: review of current advancements.
Lancet
Oncol. 2024 Oct 28;25(11):e581-e588. doi:
10.1016/S1470-2045(24)00316-4. PMID:
39481414. Review˰ ˍ
Bakas S, Vollmuth P, Galldiks N, Booth TC, Aerts HJWL, Bi WL,
Wiestler B, Tiwari P, Pati S, Baid U, Calabrese E, Lohmann P,
Nowosielski M, Jain R, Colen R, Ismail M, Rasool G, Lupo JM,
Akbari H, Tonn JC, Macdonald D, Vogelbaum M, Chang SM, Davatzikos
C, Villanueva-Meyer JE, Huang RY; Response Assessment in Neuro
Oncology (RANO) group.
Artificial
Intelligence for Response Assessment in Neuro Oncology (AI-RANO),
part 2: recommendations for standardisation, validation, and good
clinical practice.
Lancet
Oncol. 2024 Oct 28;25(11):e589-e601. doi:
10.1016/S1470-2045(24)00315-2. PMID:
39481415. Review: Recommendations˰
ˍ